PubRank

Joo Hang Kim

Author PubWeight™ 46.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009 7.50
2 Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007 3.70
3 Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010 2.48
4 Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2012 1.67
5 Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2011 1.49
6 Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2008 1.42
7 Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Support Care Cancer 2013 1.42
8 Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med 2011 1.26
9 Retracted Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J 2012 1.20
10 Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification. Ann Thorac Surg 2004 1.20
11 Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J 2012 1.16
12 Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 2012 1.16
13 A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 2010 0.99
14 Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2009 0.97
15 A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features. Oncol Rep 2008 0.95
16 Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2006 0.94
17 Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck 2004 0.91
18 Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 2005 0.91
19 Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer. Yonsei Med J 2013 0.89
20 A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma. Yonsei Med J 2003 0.88
21 Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett 2002 0.84
22 Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor. J Korean Med Sci 2013 0.82
23 The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. Yonsei Med J 2013 0.82
24 Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer 2008 0.82
25 Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer 2013 0.80
26 Clinical features of bronchogenic large cell carcinoma confirmed by surgical resection. Korean J Intern Med 2003 0.80
27 Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncol Rep 2006 0.80
28 A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2012 0.80
29 The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. Lung Cancer 2007 0.79
30 Multi-disciplinary treatment of a rare pelvic cavity ependymoma. Yonsei Med J 2007 0.79
31 Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer 2010 0.79
32 Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer Chemother Pharmacol 2007 0.79
33 Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma 2004 0.78
34 Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei Med J 2013 0.78
35 Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients. Oncology 2011 0.78
36 Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology 2008 0.78
37 Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. J Thorac Oncol 2012 0.78
38 Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. PLoS One 2012 0.77
39 EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J 2012 0.77
40 Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (hTERT). Cancer Res Treat 2003 0.76
41 The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J 2009 0.76
42 Increased Cytopathic Effect of Replicating Adenovirus Expressing Adenovirus Death Protein. Cancer Res Treat 2003 0.75
43 A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma. Yonsei Med J 2005 0.75
44 Clinical Features of Pulmonary Large Cell Neuroendocrine Carcinoma. Cancer Res Treat 2003 0.75
45 Complete response of recurrent squamous cell carcinoma of the lung: dose the dose matter? J Thorac Oncol 2009 0.75
46 Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. Anticancer Res 2012 0.75
47 Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Pharmacogenet Genomics 2016 0.75
48 Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer. Cancer Res Treat 2003 0.75
49 Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer. Cancer Res Treat 2002 0.75
50 The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. Cancer Chemother Pharmacol 2012 0.75
51 The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer. Cancer Res Treat 2003 0.75
52 Therapeutics Approaches in the Treatment of Limited Small-Cell Lung Cancer. Cancer Res Treat 2002 0.75